The present invention is generally directed to inhibitors of protein tyrosine phosphatase enzymes (PTPN1 and/or PTPN2) useful in the treatment of diseases and disorders modulated by said enzymes and having the Formula (I). Further disclosed a method of treating a disease or disorder associated with PTPN1/PTPN2, comprising of administering to a subject a compound or a pharmaceutical composition.
As part of our studies on pyrimidine derivatives, 27 4-alkyl-2-(1-piperazinyl)-5, 6-polymethylenepyrimidines and structurally related derivatives were synthesized, and their hypoglycemic activities were examined in mice treated with 2-deoxy-D-glucose. Most of the derivatives showed higher activity at a dose of 30 mg/kg p.o. than tolbutamide at a dose of 100 mg/kg p.o. The structure-activity relationships are discussed.
[EN] PEPTIDE DEFORMYLASE INHIBITORS<br/>[FR] INHIBITEURS DE PEPTIDE DEFORMYLASE
申请人:SMITHKLINE BEECHAM CORP
公开号:WO2003101442A1
公开(公告)日:2003-12-11
Novel PDF inhibitors and novel methods for their use are provided.
提供了新型PDF抑制剂和其使用的新方法。
[EN] PTPN2 INHIBITORS<br/>[FR] INHIBITEURS DE PTPN2
申请人:[en]NESS THERAPEUTICS, INC.
公开号:WO2023220572A1
公开(公告)日:2023-11-16
The present invention is generally directed to inhibitors of protein tyrosine phosphatase enzymes (PTPN1 and/or PTPN2) useful in the treatment of diseases and disorders modulated by said enzymes and having the Formula (I). Further disclosed a method of treating a disease or disorder associated with PTPN1/PTPN2, comprising of administering to a subject a compound or a pharmaceutical composition.